Shares in Acadia Pharmaceuticals surged by almost 25% in the latest trading session, finishing at $32.18.*
Performance of ACADIA Pharmaceuticals Inc over 5 years. Source: investing.com
This big jump is thanks to an exciting announcement about a deal with Neuren Pharmaceuticals. As part of the deal, Acadia will now be able to sell the drug trofinetide outside of North America. Plus, Acadia has bagged exclusive rights to a drug in development by Neuren, known as NNZ-2591, for the treatment of Rett syndrome and Fragile X syndrome. In return, Neuren will get a $100 million payment upfront, along with the possibility of further payments based on future success. Even though Acadia is expected to report a slight loss of $0.22 per share in its upcoming report, experts are feeling optimistic. They've increased their earnings estimate for the company by 7.7% over the last month, hinting at a possible increase in the share price in the future. On the other hand, Tango Therapeutics, another company in the same industry, saw a slight dip in its share price. It closed at $3.43, which is a 0.6% decrease.*
Performance of Tango Therapeutics Inc over 5 years. Source: investing.com
The company's earnings estimate for the upcoming report hasn't changed over the past month and remains at a loss of $0.35 per share.
* Past performance is no guarantee of future results
In September 2025 the U.S. central bank took a step many investors had long hoped for. After months of hesitation it cut interest rates by 25 basis points to a new range of 4.00–4.25 percent. Altho...
While Tesla’s reputation in Europe is losing its luster, Chinese competitor BYD has moved to the center of investors’ attention. Demand for Tesla’s new models remains below expectations, especially...
Gold is approaching the breakthrough of another psychological barrier, which was preceded by a slight decline. For the precious metal, it was only a short pause before reaching a new record level just a few days later. A sour...